Evidence map›Paper›PMID 42310542›Full record

ArticleBMC infectious diseases2026

Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report.

Laura C Bohorquez, Alejandro G Schijman, Freddy Perez, Hector Coto, Andrea Marchiol, Maria-Jesus Pinazo

Abstract readConsensus Statement
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura C BohorquezFIND, Chemin du Pommier 40, Le Grand Saconnex, Geneva, 1218, Switzerland. lcbohorquezs@gmail.com.
Alejandro G SchijmanINGEBI-CONICET, Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingenieria Genetica y Biologia Molecular, Dr Hector Torres, Vuelta de Obligado 2490, Buenos Aires, 1428ADN, Argentina.
Freddy PerezCommunicable Diseases Prevention, Control, and Elimination Department, Pan American Health Organization, Washington, DC, USA.
Hector CotoCommunicable Diseases Prevention, Control, and Elimination Department, Pan American Health Organization, Washington, DC, USA.
Andrea MarchiolDNDi Drugs for Neglected Diseases initiative-Latin America, Rua São José 70, sala 601, Rio de Janeiro, Brazil.
Maria-Jesus PinazoDNDi Drugs for Neglected Diseases initiative-Latin America, Rua São José 70, sala 601, Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease is a global public health issue, life-threatening parasitic disease, affecting mostly underserved communities in Latin America. Yet, 10% of infected individuals are diagnosed, and 1% receive etiological treatment. Priority actions for disease elimination by 2030 are streamlining diagnostic methods and evaluating and developing point-of-care diagnostics. We convened 44 researchers, test developers, and health authorities, to provide scientific advice and reach consensus on (i) a harmonized protocol for evaluation of rapid diagnostic tests; (ii) preferred molecular diagnostics characteristics (scope, performance, operational features, pricing, and evaluation standards); and (iii) economic impact evidence needed to have a transformational impact in primary healthcare. We considered global and national perspectives with discordant evidence from multiple disciplines. Our outcomes provide a reference on practical applications and recommendations to promote test development and evaluation. Finally, we debate about the appropriate approach moving forward to meet the diagnostic gap, and propose how investments could be stimulated.

Indexed as

Chagas DiseaseMolecular Diagnostic TechniquesCost-Benefit AnalysisHumansLatin AmericaRapid Diagnostic TestsTrypanosoma cruziConsensus meetingCost-effectivenessExpert recommendationsPoint-of-care testsTrypanosoma cruzi

Identifiers

PMID42310542
PMCPMC13276932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.